One Step Ahead: Preventing Tumor Adaptation to Immune Therapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, improving survival in several cancer types.
• However, many patients do not respond to ICIs, and acquired resistance or severe adverse events limit their efficacy.
• Mechanisms of resistance involve T-cell exhaustion, upregulation of alternate checkpoints (e.g., LAG-3), persistent interferon signaling, and immunosuppressive myeloid cells within the tumor microenvironment (TME).

Purpose of the Study:

• To review the mechanisms of resistance to immune checkpoint inhibitors in solid tumors.
• To highlight emerging therapeutic strategies targeting alternate immune checkpoints and pathways involved in immune suppression.
• To discuss recent clinical developments and approvals for novel cancer immunotherapies.

Main Methods:

• Literature review of studies on immune checkpoint inhibitors and cancer resistance mechanisms.
• Analysis of clinical trial data for novel immunotherapies targeting alternate checkpoints and immunosuppressive pathways.
• Examination of the role of T-cell exhaustion, LAG-3, interferon signaling, and myeloid cells in the TME.

Main Results:

• Chronic immune stimulation can lead to T-cell exhaustion and upregulation of alternative checkpoints like LAG-3.
• Persistent interferon signaling in the TME can induce epigenetic changes in cancer cells, promoting immune evasion.
• Immune-suppressive macrophages contribute to tumor progression by hindering effective anti-tumor immune responses.
• New therapies targeting LAG-3, phosphoinositide 3-kinase gamma, and JAK inhibitors show clinical promise.

Conclusions:

• Understanding resistance mechanisms is crucial for advancing cancer immunotherapy.
• Targeting alternate immune checkpoints and immunosuppressive pathways offers new avenues for cancer treatment.
• Emerging therapies demonstrate potential to overcome resistance and improve outcomes for a broader range of cancer patients.